Critical Outcome Technologies amalgamates with DDP Therapeutics

This amalgamation completes the process of integrating the small cell lung cancer (SCLC) molecule library of DDP with the research development operations of Critical Outcome Technologies (COTI).

Since acquisition COTI has added significant value to the SCLC library as part of its commercialization strategy for these small molecules with emphasis on the lead compound COTI-2.

COTI has also advanced other candidates in the SCLC library into preclinical development. COTI-4 and COTI-58 will enter into synthesis in June 2008. COTI-219 is expected to undergo mechanism of action experiments in July 2008.

Wayne Danter, president and chief scientific officer of COTI, said: “I am pleased to report positive developments in our oncology program as a result of the acquisition of DDP. The ongoing development and progress of our oncology drug candidates has helped build a robust pipeline for COTI and augments our business development opportunities.”